Coripharma is a European pharmaceutical company, built on solid heritage. Our experienced team offers out-licensing and contract manufacturing services to pharmaceutical companies. Coripharma specializes in generic pharmaceutical products, solid oral dosage forms.

Coripharma

Coripharma has received the 2026 Gender Balance Recognition for achieving gender balance at the highest level of management. We are proud of this recognition, which reflects the diversity that has long characterised our company, where women have made up the majority of both our workforce and management team. Diverse leadership teams make better decisions, foster a stronger culture and deliver better results for the company, our customers and society as a whole.

We would like to sincerely thank the Gender Balance initiative for this recognition.

Equality is not a goal that is ever fully achieved, but an ongoing commitment—and we intend to keep doing even better.

Coripharma is pleased to announce continued progress in the development of Enzalutamide 40 mg, 80 mg and 160 mg tablets.  

Following the successful completion of two bioequivalence (BE) studies under fed and fasted conditions, Coripharma is finalizing the dossier in Q4 2026, with submission planned for Q1 2027.  

This represents an important milestone in the development program, and we are currently evaluating registration opportunities for the product.

Dadi has been appointed Director Supply Chain Operations at Coripharma and will join the company's Executive Management Team.

Dadi brings more than 15 years of experience in the pharmaceutical industry, with extensive expertise in supply chain operations, business development, and cross-functional collaboration. Since joining Coripharma in 2022, he has worked on contract manufacturing initiatives and played an increasingly important role in the business development of the company's own-developed products. Throughout his career, Dadi has built strong relationships with international stakeholders, suppliers, and strategic partners, providing him with a broad understanding of the global pharmaceutical value chain and positioning him well for his new role.

"It is a truly exciting opportunity to lead Coripharma's Supply Chain Operations. I look forward to taking on this new role and continuing to build a strong and efficient supply chain organization that supports the company's continued growth," says Dadi

"It is particularly rewarding to fill such an important position from within our own organization. It reflects the strength, expertise, and experience we have built at Coripharma and provides an important foundation as we continue to grow the company. Dadi possesses extensive knowledge and experience in supply chain management. Efficient and reliable delivery of products and services from suppliers to customers is a key driver of Coripharma's continued growth and success, and I am confident that Dadi will play an important role in that journey," says Jonina Gudmundsdóttir, CEO.

Coripharma is a pharmaceutical company specializing in the development, manufacturing, and export of generic medicines. The company currently employs approximately 230 people.

Dadi Oskarsson Appointed Director Supply Chain Operations at Coripharma

Coripharma is pleased to announce the successful completion of the pivotal bioequivalence (BE) studies for Migalastat.

This represents an important milestone in the development program, with dossier completion targeted for Q1 2028.

Coripharma is continuing to advance the development of Migalastat and welcomes discussions with potential partners.

Migalastat Pivotal Bioequivalence Studies Successfully Completed

About us

Services

Sustainability

Careers

Migalastat Pivotal Bioequivalence Studies Successfully Completed

More news

Gender Balance Recognition 2026

Enzalutamide Dossier Nearing Completion

Dadi Oskarsson Appointed Director Supply Chain Operations at Coripharma

+354 4206700